PPT-From LP2 to 2S-LP2: discovery of a biased dual-target mu/delta opioid receptor agonist

Rita Turnaturi 1 Carmela Parenti 2 Girolamo Calo 3 Santina Chiechio 2 Agostino Marrazzo 1 and Lorella Pasquinucci 1 1 Department of Drug Sciences Medicinal Chemistry Section University of Catania Catania Italy . Louis 188 AirTran Delta Washington DC 1 AirTran Zak Fallows. pharmacology@mit.edu. 2013-11-23. ESP Splash (Saturday). These slides are available online, along with fun 5-minute quizzes and other materials:. http://. datb.mit.edu. /. Are You in the Right Room?. David Kan, M.D.. University of California. San Francisco. VA Medical Center. San Francisco. History of Opioids. The “Pod of Pleasure”. OTC Opiates. Opium. Smoker. Opium in San Francisco. Gentlemen prefer…opium. Jessica Tagerman, . PharmD. , . RPh. Pharmacokinetics & pharmacodynamics. Pharmacodynamics: What the drug does to the body. Pharmacokinetics: What the body does to the drug. pharmacodynamics. “What the drug does to the body”. Lectures. Drug Mechanisms. Receptor Interactions. Pharmacokinetics. Pharm definitions and drug selectivity. Drug= A chemical substance that interacts with a biological substance to produce a physiological effect. Daniel P. Edney MD FACP. Objectives. Review common complications. Review CDC treatment guidelines. Review basic exit strategies. Common Complications. Tolerance. Dependency. Opioid Induced Hyperalgesia. Pain. . Pain. persists Pain persists. or increases or increases. 1. . Non. -. opioid. ± adjuvant. 2. Weak . opioid. ± non-. opioid. ± adjuvant. 3. Strong . opioid. Copyright 2019. Jason McLott. All Rights Reserved. . Disclosure Statement. I have no financial relationships with any commercial interest related to the content of this activity. I will discuss the off label use of many medications. Anna Maria Nardiello. 1,. *, Lucia Sessa. 1,2. , Jacopo Santoro. 1. and Stefano Piotto. 1,2. 1. . Department of Pharmacy, University of Salerno, . Fisciano. , 84084, Italy. 2. . Research. Centre for . an . unpleasant sensation that can be either acute or chronic and is a consequence of complex neurochemical processes in the peripheral and central nervous systems (. CNS. Alleviation . of pain depends on the . MD., DA., DNB, Dip. Diab., PhD (physiology). Dip. Software based statistics- . IDRA, CUGRA . What are they ? . Minor changes in the structure of an opioid agonist. . convert the drug into an opioid antagonist at one or more of the opioid receptor sites . Archana Vidya Boopathy,. 1. Anurag Nekkalapudi,. 1. Bhawna Sharma,. 1. Sophie Schulha,. 2. . Raphaela. Wimmer,. 2. Debi Jin,. 1. Janette Sung,. 1. Jeffrey Murry,. 1. Mark Nagel,. 1. Brian Carr,. This . project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under contract number HHSH250201600015C. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.. Pharmacodynamics. Dennis Paul, Ph.D.. dpaul@lsuhsc.edu. Learning Objectives:. Understand the theoretical basis of drug-receptor interactions.. Understand the determinants and types of responses to drug-receptor interactions..